Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double Blind, Two Arm Study to Investigate the Effects of BNC210 Tablet Formulation Compared to Placebo in Adults With Post-Traumatic Stress Disorder (PTSD)

NCT04951076 is registered in ClinicalTrials.gov with Bionomics Limited as lead sponsor.

NCT NCT04951076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04951076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double Blind, Two Arm Study to Investigate the Effects of BNC210 Tablet Formulation Compared to Placebo in Adults With Post-Traumatic Stress Disorder (PTSD)
Lead sponsor
Bionomics Limited
Phase
Phase 2
Overall status
Completed
Start date
July 27, 2021
Completion date
August 14, 2023
Enrollment
212 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

post-traumatic stress disorder